2019-08-06T12:38:02-05:00 2018-09-30 ERNST & YOUNG US LLP 200 CLARENDON STREET BOSTON MA 021165072 990 2017-10-01 042263040 Dana-Farber Cancer Institute Inc % Melissa Chammas DANA 6176323000 450 Brookline Avenue BP418 Boston MA 02215 Michael Reney CFO 6176323000 2019-08-01 true BARBARA E HUNT P00916443 6172662000 2019-07-23 164.57.159.253 04750420192185000000 2019-08-06 P D33A081E80969AF923AF04AA0904B93B9A5DC5C8 36455B2BDA99E2162F05488401542DAAB5EDB38C 2017 2019-02-21 02:37:17Z Laurie H Glimcher MD 450 BROOKLINE AVE Boston MA 02215 1759592772 false X www.dana-farber.org X 1951 MA THE MISSION OF DFCI IS TO PROVIDE EXPERT, COMPASSIONATE CARE TO CHILDR COMPASSIONATE CARE TO CHILDREN AND ADULTS WITH CANCER & ADVANCE THE TREATMENT, CURE, AND PREVENTION OF CANCER & RELATED DISEASES. 58 57 6065 600 4330918 3775892 511844582 561378936 960793496 1151473141 1818484 25907335 20654663 16378704 1495111225 1755138116 4629223 8963365 0 0 497895456 537676542 2825453 3832226 35482803 1022889127 1130830256 1528239259 1681302389 -33128034 73835727 2599191879 2890706000 1067661784 1135834597 1531530095 1754871403 THE MISSION OF DANA-FARBER CANCER INSTITUTE IS TO OPERATE, CONDUCT AND SUPPORT AN INSTITUTE FOR RESEARCH INTO THE CAUSES, TREATMENT AND PREVENTION OF CANCER AND OTHER DISEASES IN CHILDREN AND ADULTS AND TO PROVIDE FOR THE CARE, TREATMENT AND NURSING OF PERSONS HAVING SUCH DISEASES, AND IN FURTHERANCE OF THE FOREGOING, TO CONSTRUCT, OPERATE AND MAINTAIN A HOSPITAL OR HOSPITALS, A CANCER CENTER AND OTHER FACILITIES IN BOSTON, MASSACHUSETTS, ANYWHERE IN THE UNITED STATES OF AMERICA OR ELSEWHERE IN THE WORLD TO PROVIDE FOR PERSONS WITH CANCER AND OTHER DISEASES REGARDLESS OF AGE; TO PROMOTE HEALTH CARE IN COMMUNITIES AROUND THE WORLD BY EDUCATING AND SUPPORTING OTHER PROVIDERS IN EFFECTIVE CANCER CARE AND RESEARCH; AND TO CARRY ON ALL ACTIVITIES RELATED OR INCIDENT THERETO INCLUDING, BUT WITHOUT LIMITATION HERETO, RESEARCH, STUDY, TEACHING, CLINICAL INVESTIGATION, CARE OF PATIENTS AND TRAINING OF MEDICAL STUDENTS, SCIENTISTS, NURSES, RESEARCH ASSISTANTS AND PARAMEDICAL PERSONNEL. false false 987674709 0 1175274917 Clinical Care As one of the leading cancer centers in the world, Dana-Farber provides compassionate, comprehensive and personalized care to adults and children with cancer, blood disorders and related diseases. In 2018, our expert clinicians and caregivers at our specialized treatment centers worked together to deliver the latest therapies to our patients through 1,304 inpatient admissions, 346,805 outpatient MD visits and 176,630 infusion treatments. SINCE ITS FOUNDING IN 1947 BY SIDNEY FARBER, MD, DANA-FARBER HAS FOLLOWED HIS VISION FOR A CANCER CENTER THAT IS JUST AS DEDICATED TO DISCOVERIES IN CANCER RESEARACH AS IT IS TO DELIVERING EXPERT COMPASSIONATE CARE. DANA-FARBER IS A FOUNDING MEMBER OF DANA-FARBER/HARVARD CANCER CENTER AND ONE OF 49 NCI-DESIGNATED COMPREHENSIVE CANCER CENTERS IN THE U.S. DANA-FARBER IS THE ONLY HOSPITAL RANKED IN THE TOP FOUR NATIONALLY BY U.S. NEWS AND WORLD REPORT IN BOTH ADULT AND PEDIATRIC CANCER CARE. IN 2018, WE OFFERED MORE THAN 1,100 CLINICAL TRIALS. 521249580 5373333 0 Research Scientific work at Dana-Farber is based on the premise that basic and clinical investigation are complementary and reinforcing activities. To encourage this cross-pollination of ideas, the Institute has developed an organizational framework that fosters collaborations among investigators from different disciplines. The result is an intense scientific impact on a group of diseases that continue to represent one of humanitys greatest health challenges. SOME RECENT ADVANCES INCLUDE: Sensitizing cancer cells to chemotherapy: Dana-Farber scientists showed that experimental diabetes drugs can make certain types of cancer cells more vulnerable to traditional chemotherapy agents. Survey of cancer metabolites: With researchers at other institutions, DFCI scientists compiled the first systematic survey of the products of biochemical reactions within cancer cells and their relation to the advance of the disease. The results provided scientists around the world with a curated dataset with which to track changes in these protein products, called metabolites, in cancer cells and potentially uncover vulnerabilities that can be targeted by new therapies. Preventing Metastasis: A study by DFCI investigators suggested it may be possible to prevent tumors from recurring and to eradicate metastatic growths by implanting a gel with an immune system-stimulating drug during surgical removal of a tumors. The technique, performed in animal models of breast cancer, cured a higher proportion of the animals than delivery of the drug by other techniques. Predicting Immunotherapy Effectiveness: DFCI researchers discovered a genetic signature in melanoma cells that indicates which melanomas are unlikely to respond to the immunotherapy agent ipilimumab work that may help doctors identify patients most likely to benefit from the drug. Combination Therapy for Ovarian Cancer: A combination of the immunotherapy drug pembrolizumab and the PARP inhibitor niraparib can be significantly more effective than either drug alone in women with hard-to-treat ovarian cancer, a clinical trial led by DFCI investigators showed. Protecting against HIV-1 Infection: Compounds that mimic key proteins on white blood cells can inactivate HIV-1, the virus that causes AIDS, and potentially protect against exposure to the virus, DFCI scientists reported. The findings potentially offered a promising way to unlock the promise of AIDS vaccines. Lowering Risk of Colon Cancer Recurrence: Patients treated for non-metastatic colon cancer may sharply reduce the risk that the disease will return by following a diet low in carbohydrates and other foods that raise insulin levels, a study by DFCI investigators found. New Approaches to Early Myeloma Treatment: DFCI scientists and an international team of researchers tracked the genomic changes that occur as smoldering multiple myeloma (SMM) advances to myeloma, laying the groundwork for tests to identify patients whose SMM is likely to advance and who could benefit from prompt treatments. The Organoid Advantage: "Organoids" grown from patients ovarian cancer cells proved more accurate than DNA sequencing in predicting whether tumors were likely to respond to certain chemotherapy drugs and combining the two techniques worked even better DFCI scientists reported. Combination Therapy Boosts Survival of Patients with Melanoma: Fifty-three percent of patients with advanced melanoma who received a two-drug immunotherapy treatment in a clinical trial survived at least four years, an unprecedented long-term outcome in the disease, DFCI investigators reported. Uncovering Vulnerabilities: DFCI scientists uncovered a previously unknown molecular vulnerability in two rare, aggressive, and hard-to-treat cancers synovial sarcoma, and malignant rhabdoid tumors and said it may be possible to exploit this susceptibility with targeted drugs. PARP Inhibitors and the Immune System: Drugs known as PARP inhibitors, which undercut cancer cells by inhibiting tumor their ability to repair damaged DNA, can also help spark an immune system attack on the cells, DFCI scientists found. The findings suggest that combining PARP inhibitors with immunotherapy can extend remissions triggered by the drugs. Neoantigen Vaccine: DFCI scientists showed that personalized "neoantigen" vaccine could spur an immune response against glioblastoma, a form of brain cancer that previously hadnt responded well to immunotherapieS. 20262510 3590032 0 COMMUNITY BENEFITS The role of Dana-Farber's Community Benefits office is to support the Institute's goal to reduce cancer risk among medically underserved populations. To that end, we work with city and state health departments, community partners, and Boston-based coalitions to assess and monitor the needs of local residents with respect to cancer control. We are on the front lines of supporting and collaborating on programs designed to eliminate disparities in breast, colon, skin, and prostate cancer; educate diverse populations about tobacco cessation, human papillomavirus (HPV) prevention and screening, and clinical trials; and strengthen the support system for medically underserved populations. In short, we are committed to making Dana-Farber's care and research findings are more accessible to everyone within and outside its walls. In FY 2018: Dana-Farbers Mammography Services provided close to 2,300 mammograms on the van and at the mammography suite in Roxbury. 1,066 individuals received breast health education on the mammography van or at a community outreach event. A total of 56 community members have been trained as Lay Health Advisors in breast cancer, screening guidelines, and health promotion and outreach strategies. 1,414 community members were reached through Sun Safety Education and Screening events, with an average of 59 participants per event. A total of 3,254 individuals were reached through 147 community education, outreach and screening events. 1529186799 true true false true false false false false false true true false false true true false false true false false true false false true true false true true true true true true false false false false false true false false false false true false false false false true true true true false true 650 0 true 6065 true true true true CJ false false false true true false false false false X 58 57 true false true false false false false true true false false true true true true true true true true false AL AK AZ CA CO CT DC DE FL GA HI ID IL IN IA KS KY LA ME MH MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VI VA WA WV WI WY X Melissa Chammas 6175828311 450 Brookline Ave BP418 Boston MA 02115 X Alexander Susan Trustee 1.0 0.0 X 0 0 0 Beale Jeffrey Trustee (AS OF 1/29/18) 1.0 0.0 X 0 0 0 Bekenstein Joshua Trustee & Chairman 2.0 0.0 X X 0 0 0 Berger Harvey Trustee (AS OF 1/29/18) 1.0 0.0 X 0 0 0 Berkowitz Roger Trustee 1.0 0.0 X 0 0 0 Berylson Amy Trustee 1.0 0.0 X 0 0 0 Beschloss Afsaneh Trustee (AS OF 1/29/18) 1.0 0.0 X 0 0 0 Blum Betty Ann Trustee 1.0 0.0 X 0 0 0 Brock-Wilson Jane Trustee 1.0 0.0 X 0 0 0 Champa Michael Trustee (TERM ENDED 01/29/18) 1.0 0.0 X 0 0 0 Chandra Monica Trustee 1.0 0.0 X 0 0 0 Cox Howard Trustee 1.0 0.0 X 0 0 0 Curtin Neal Trustee & Secretary 2.0 0.0 X X 0 0 0 Daley Karen Trustee 1.0 0.0 X 0 0 0 DaSilva Kevin Trustee 1.0 0.0 X 0 0 0 Dobson Sean Trustee 1.0 0.0 X 0 0 0 Farrington Thomas Trustee 1.0 0.0 X 0 0 0 Fine Stephen Trustee 1.0 0.0 X 0 0 0 Foulkes Helena Trustee (TERM ENDED 11/13/17) 1.0 0.0 X 0 0 0 Gibson Nancy Trustee 1.0 0.0 X 0 0 0 Glimcher Laurie Trustee, President and CEO 42.0 8.0 X X 1344224 35137 245906 Greenthal Jill Trustee 1.0 0.0 X 0 0 0 Gross Phillip Trustee 1.0 0.0 X 0 0 0 Hadley Christopher Trustee 1.0 0.0 X 0 0 0 Jaffe Alison Trustee 1.0 0.0 X 0 0 0 Jamieson Jane Trustee 1.0 0.0 X 0 0 0 Janower Andrew Trustee 1.0 0.0 X 0 0 0 Knez Brian Trust&Tres(TERM ENDED 1/29/18) 2.0 0.0 X X 0 0 0 Koppel Steven Trustee 1.0 0.0 X 0 0 0 Koster Stephen Trustee 1.0 0.0 X 0 0 0 Kyle Amy Trustee 1.0 0.0 X 0 0 0 LaTorre James Trustee 1.0 0.0 X 0 0 0 Lubin Richard Trustee & Vice-Chairman 2.0 0.0 X X 0 0 0 Lucas Bradley Trustee 2.0 0.0 X 0 0 0 Lucchino Lawrence Trustee 1.0 0.0 X 0 0 0 Marcus Paul Trustee 1.0 0.0 X 0 0 0 Martin Demond Trustee 1.0 0.0 X 0 0 0 McCain Tracey Trustee 1.0 0.0 X 0 0 0 Medel Roger Trustee 1.0 0.0 X 0 0 0 Norberg Joseph Trustee 1.0 0.0 X 0 0 0 O'Connor John Trustee & Treas(as of 1/29/18) 2.0 0.0 X X 0 0 0 Packman Karen Linde Trustee 1.0 0.0 X 0 0 0 Palandjian Peter Trustee 1.0 0.0 X 0 0 0 Pasquarello Theodore Trustee 1.0 0.0 X 0 0 0 Perini Jennifer Trustee 1.0 0.0 X 0 0 0 Perlmutter Steven Trustee 1.0 0.0 X 0 0 0 Poduska Susan Trustee 1.0 0.0 X 0 0 0 Reynolds Robert Trustee 1.0 0.0 X 0 0 0 Rosenthal Harvey Trustee (TERM ENDED 01/29/18) 1.0 0.0 X 0 0 0 Sachs Robert Trustee 1.0 0.0 X 0 0 0 Schlager Eric Trustee (AS OF 1/29/18) 1.0 0.0 X 0 0 0 Sen Laura Trustee 1.0 0.0 X 0 0 0 Stansky Robert Trustee 1.0 0.0 X 0 0 0 Stratford Sandra Trustee 1.0 0.0 X 0 0 0 Stecher Esta Trustee (AS OF 1/28/18) 1.0 0.0 X 0 0 0 Sullivan Ronald Trustee 1.0 0.0 X 0 0 0 Terrana Beth Trustee 1.0 0.0 X 0 0 0 Ting David Trustee 1.0 0.0 X 0 0 0 Tocio Mary Ann Trustee 1.0 0.0 X 0 0 0 Whelan Lori Trustee (AS OF 1/29/18) 1.0 0.0 X 0 0 0 Williams Frederica Trustee 1.0 0.0 X 0 0 0 Yeshwant Krishna Trustee 1.0 0.0 X 0 0 0 Boskey Richard S ESQ Asst. SEC. & General Counsel 50.0 0.0 X 626612 0 66638 Puhy Dorothy COO & EVP 50.0 0.0 X 924842 0 44492 Reney Michael CFO and Asst. Treasurer 50.0 0.0 X 677036 0 43666 Bartel Sylvia R Ph MHP VP of Pharmacy Services 50.0 0.0 X 274871 0 70410 Bunnell Craig A MD MBA MPH Chief Medical Officer 50.0 0.0 X 725753 0 44765 Gettleman Wendy VP of Facilities Management 50.0 0.0 X 299120 0 59231 Johnson Bruce Chief Clinical Research Office 50.0 0.0 X 640151 0 57386 Megdal Maria SVP of Institute Operations 50.0 0.0 X 478521 0 56340 Memmott Drew SVP Research Administration 50.0 0.0 X 444394 0 63189 Paresky Susan SVP of Development 50.0 0.0 X 739619 0 59169 Rollins Barrett J MD PHD Chief Scientific Officer 50.0 0.0 X 685614 0 56925 Ebert Benjamin MD PHD Chair of Med Oncology 50.0 0.0 X 205073 0 21110 Liebow Elizabeth SVP Business Dev Clinical Plan 50.0 0.0 X 355334 0 63483 Nadler Lee MD SVP for Experimental Medicine 50.0 0.0 X 716507 0 60104 Soiffer Robert MD Chief of Hemotologic Malig. 50.0 0.0 X 697270 0 63551 Winer Eric MD SVP,CHF CLINICAL STRAT OFFICER 50.0 0.0 X 741255 0 57451 Hahn William MD PHD CHIEF RESEARCH STRATEGY OFFICE 50.0 0.0 X 673135 0 42288 Constantine Michael MD Milford Med Dir-Hematology 50.0 0.0 X 696927 0 54310 Griffin James D MD Former Key Employee 50.0 0.0 X 722813 0 61790 Benz Edward J JR MD Former Officer 42.0 8.0 X 1365731 0 54783 Bird Karen Former Officer 50.0 0.0 X 390099 0 31404 Stone Richard M MD Former Key Employee 50.0 0.0 X 471225 0 66548 Sallan Stephen E MD Former Key Employee 50.0 0.0 X 544378 0 65177 15440504 35137 1510116 1175 true true false Partners Healthcare System Inc PO Box 3715 Boston MA 02241 Information Systems 102925878 Brigham and Women's Hospital 75 Francis St Boston MA 02115 Medical Services 66969845 SKANSKA USA Building Inc 101 Seaport BLVD Boston MA 02110 Building Contractor 27687189 Brigham and Women's Physicians Org 111 Cypress St Brookline MA 02445 Medical Services 16567026 SOUTH SHORE HOSPITAL 55 FOGG RD SOUTH WEYMOUTH MA 02190 MEDICAL SERVICES 13708999 450 244934 25589349 139983669 395560984 9638089 561378936 NET PATIENT SERVICE REVENUE 621110 1141349645 1141349645 0 0 NETWORK COLLABORATION 900099 10123496 10123496 0 0 1151473141 2105559 2105559 0 5203697 5203697 2320722 2320722 0 2320722 2320722 23801776 23801776 23801776 23801776 923193 25589349 4454656 -3531463 -3531463 0 0 0 0 0 0 PARKING LOT REVENUE 812930 5813650 4330918 1482732 FOOD SERVICE REVENUE 722210 4038106 0 4038106 WCB BOUTIQUE INCOME 446199 1073088 0 1073088 1460904 1460904 12385748 1755138116 1175274917 4330918 14153345 7519503 7519503 1443862 1443862 0 0 0 0 8456302 2886796 4829887 739619 3494246 1738416 1755830 0 422716911 363121494 37355417 22240000 28375448 24006807 2868513 1500128 44077581 37291462 4455864 2330255 30556054 25851689 3088954 1615411 6957448 4570989 2386459 0 16921115 9943177 6964703 13235 616400 0 616400 0 1198442 1198442 0 0 3832226 3832226 0 0 0 0 154341625 138687340 15447540 206745 5986905 4283080 903474 800351 36504772 31021760 4694607 788405 57065621 52134937 4888456 42228 0 0 0 0 104385476 86685011 17695497 4968 10162377 9066485 1028403 67489 0 0 0 0 3165125 670714 1714443 779968 26254690 26254690 0 0 0 0 0 0 88886508 86104154 2782354 0 2564605 87995 2476610 0 OTHER PATIENT CARE EXPENSE 24168699 24168699 0 0 Miscellaneous 60732167 59531016 679376 521775 Medical Supplies Expense 519646038 519646038 0 0 Bad Debt Expense 11272243 11272243 0 0 1681302389 1529186799 116632787 35482803 0 0 0 112831937 178566040 44473370 63138970 110362614 139003733 720707 509319 0 0 0 0 21750551 29714527 30981820 45380890 1776990103 821301113 964186553 955688990 0 0 0 0 0 0 7894580 7894580 1305989747 1470808951 2599191879 2890706000 142737917 135803630 0 0 0 0 539978780 534438729 0 0 0 0 74174396 72968294 0 0 310770691 392623944 1067661784 1135834597 X 725849905 846457749 612694419 703139823 192985771 205273831 1531530095 1754871403 2599191879 2890706000 X 73835727 0 0 0 0 149505581 X false true X true true true X 897 427883303 453735920 511844582 561378936 1954843638 0 0 897 427883303 453735920 511844582 561378936 1954843638 0 1954843638 30943986 17299053 13734456 9251603 9629978 80859076 0 15163484 14345239 15146613 17212855 23432437 85300628 2121003342 4452238465 0.92166 0.93213 X true true false 0 true 0 false 0 true 1043023 true 155419 false 0 false 0 1198442 false Schedule C Part II-B VAN SCOYOC & ASSOCIATES - PROVIDED FEDERAL LEGISLATIVE CONSULTING FOR DFCI. MCDERMOTT, QUILTY & MILLER LLP - PROVIDED STATE LEGISLATIVE AND GOVERNMENT RELATIONS CONSULTING ON HEALTH INTERESTS TO DFCI. CONFERENCE OF BOSTON HOSPITALS PROVIDED STATE AND FEDERAL LOBBYING SUPPORT TO DFCI. ALLIANCE OF DEDICATED CANCER CENTERS REPRESENTS THE NATION'S TEN FREESTANDING CANCER CENTERS. WE WORK TOGETHER ON FEDERAL REGULATORY, LEGISLATIVE AND REIMBURSEMENT ISSUES UNIQUE TO DEDICATED CANCER CENTERS. DFCI IS A MEMBER OF THE AMERICAN HOSPITAL ASSOCIATION AND THE MASSACHUSETTS HOSPITAL ASSOCIATION, NOT-FOR-PROFIT ORGANIZATIONS THAT REPRESENT AND ADVOCATE FOR THE COLLECTIVE INTERESTS OF THEIR MEMBER HOSPITALS AND HEALTH SYSTEMS THROUGH LEADERSHIP IN PUBLIC ADVOCACY, EDUCATION, AND INFORMATION. A PORTION OF THE MEMBERSHIP DUES TO THESE ORGANIZATIONS ARE USED FOR LOBBYING ACTIVITIES. ON OCCASION, DFCI EXECUTIVE LEADERSHIP MEET WITH STATE AND FEDERAL ELECTED OFFICIALS TO ADVOCATE FOR THE PASSAGE OF LEGISLATION AND FUNDING TO ADVANCE CANCER RESEARCH AND TREATMENT, AND LEGISLATION TO SUPPORT SERVICES FOR CANCER PATIENTS AND CANCER SURVIVORS. IN ADDITION, DFCI SUBMITS LETTERS AND/OR TESTIMONY TO ELECTED OFFICIALS AND POLICY MAKERS on these issues. 276248000 12288000 30131000 17089000 301578000 252162000 9815000 32600000 18329000 276248000 238449000 10151000 20243000 16681000 252162000 250650000 7603000 -4102000 15702000 238449000 231119000 11556000 22937000 14962000 250650000 0.68000 0.32000 false true true 7640445 7640445 1189288643 464354530 724934113 130351821 83738001 46613819 395817842 273208581 122609261 53891352 53891352 955688990 INTEREST IN DANA-FARBER, INC. 1333082616 MISCELLANEOUS ASSETS 102820335 INTEREST IN DFCCN 34906000 1470808951 0 AMOUNTS DUE 3RD PARTY PAYOR 53458490 RESEARCH ADVANCES 125586000 PROV FOR MED MALPRACTICE CLAIM 1335000 SWAP VALUATION LIABILITY 34458000 mISCELLANEOUS LIABILITIES 177786454 392623944 SCHEDULE D, PART V, QUESTION 4 DANA-FARBER, INC (DFI) A RELATED ORGANIZATION OF DANA-FARBER CANCER INSTITUTE, INC. (DFCI) HOLDS THE ENDOWMENTS FOR DFCI AND THEREFORE REPORTS THE ENDOWMENT FUNDS ON DFI'S 990 ACCORDINGLY. AS DESCRIBED IN DETAIL IN THE CONSOLIDATED AUDITED FINANCIAL STATEMENTS, THE INSTITUTE'S ENDOWMENTS CONSIST OF NUMEROUS INDIVIUDAL FUNDS ESTABLISHED FOR A VARIETY OF PURPOSES. THESE ENDOWMENTS CONSIST SOLELY OF DONOR-RESTRICTED ENDOWMENT FUNDS. AS REQUIRED BY GENERALLY ACCEPTED ACCOUNTING PRINCIPLES, NEW ASSETS ASSOCIATED WITH ENDOWMENT FUNDS ARE CLASSIFIED AND REPORTED BASED ON THE EXISTENCE OR ABSENCE OF DONOR-IMPOSED RESTRICTIONS. ALL USES OF THE ORGANIZATION'S ENDOWMENT FUNDS ARE DIRECTLY RELATED TO THE INSTITUTE'S EXEMPT MISSION AND PURPOSES. Central America and the Caribbean Program services Jointly owned for insu 3569990 Central America and the Caribbean Program services subcontracted research 58032 East Asia and the Pacific Program services subcontracted research 1222265 East Asia and the Pacific Program services research and education 474118 Europe (Including Iceland and Greenland) Program services subcontracted research 1038928 Middle East and North Africa Program services subcontracted research 24479 North America Program services subcontracted research 763675 South Asia Program services subsontracted research 509087 South America Program services research and education 1208557 Sub-Saharan Africa Program services subcontracted reserach 1096679 9965810 9965810 true false true false false true X X X X X X X true TRUESENSE MARKETING Direct Mail Consulting false 12900205 3816476 9083729 Turnkey Consulting false 15750 12900205 3832226 9083729 AL AK AS AZ AR CA CO CT DC FM FL GA HI ID IL IN IA KS KY LA ME MH MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX VI UT VT VA WA BMJF Walk 8912000 8733269 178731 225192 29055 2800 1254880 DFMC 6480960 6359391 121569 177995 14100 599236 15 11119582 10496689 622893 715634 70229 488890 876645 26512542 25589349 923193 1118821 113384 491690 2730761 4454656 -3531463 true true X true X true X true true true false true true 11795975 4449041 7346934 0.00440 77613581 58517574 19096007 0.01140 89409556 62966615 26442941 0.01580 4839055 4839055 0.00290 5611872 535666 5076206 0.00300 574484962 455558059 118926903 0.07120 1226708 1226708 0.00080 586162597 456093725 130068872 0.07790 675572153 519060340 156511813 0.09370 695481 695481 0.00040 470500 470500 0.00030 1165981 1165981 0.00070 true 11272243 112722 266757419 287196143 -20438724 X true true 1 1 DANA-FARBER CANCER INSTITUTE INC 450 BROOKLINE AVE BOSTON MA 02215 www.dana-farber.org 2335 X X X D-F/BWH @ Milford, and SOUTH Shore D-F @ st elizabeth's DANA-FARBER CANCER INSTITUTE INC 1 false false true X X X X X X X X X 15 true false false true X dana-farber.org X true 15 true dana-farber.org false true X 150. 300. X true true X X X true X dana-farber.org/PFA X dana-farber.org/PFA X dana-farber.org/PFA X X X X X X true X false X X X true X true false Part V, Line 5 Dana-Farber Cancer Institute contracted Health Resources in Action (HRiA), a non-profit public health organization, to conduct the most recent 2016 (Tax Year 2015) community health needs assessment. The CHNA assessment was guided by a participatory, collaborative approach, integrating existing secondary data on social, economic, and health issues in the region with qualitative information from three focus groups with community residents and fifteen interviews with community stakeholders from March 2016 through June 2016. Overall this process engaged over 150 people. Focus groups were held with 39 community residents drawn from the region representing English-speaking adult cancer survivors, Spanish-speaking adult cancer survivors and community members residing in DFCI priority neighborhoods. Additionally, a total of 22 individuals representing the DFCI community as well as the region at large were engaged in key informant and group discussions. Key informants represented a number of sectors including academic research, health care, public health, social service, and city government. Discussions explored participants' perceptions of their communities, priority health concerns, perceptions of cancer and related services across the cancer continuum (prevention, screening, treatment, survivorship), and suggestions for future services and resources to address these issues. A semi-structured moderator's guide was used across all discussions to ensure consistency in the topics covered. Participants for the focus groups were recruited by Health Resources in Action, YMCA of Dorchester, the Dana-Farber/Harvard Cancer Center, and Dana-Farber Cancer Institute. It was also a priority to recruit adults from traditionally underserved populations, including the low-income and those who do not speak English as a primary language. In addition to the primary data collection, Conference of Boston Teaching Hospitals (COBTH), of which DFCI is an active member, partnered with the Boston Alliance of Community Health (BACH), the city-wide coalition comprised of neighborhood coalitions, to conduct three focus groups with community residents in early Spring 2016 delving into people's experiences with the social determinants of health. A total of over 80 community residents participated. The outputs of the neighborhood-level meetings are included in the findings of Dana-Farber's 2016 CHNA and reflect the commitment of Dana-Farber and other COBTH member hospitals to work together in addressing the social, economic, and environmental factors that impact health, well-being, and more specifically, cancer outcomes in our surrounding communities. Additionally, four separate groups were engaged in June 2016 to discuss the CHNA's preliminary data findings. In these sessions, HRIA presented key qualitative and quantitative findings in a 45-minute presentation each to the following DFCI committees: External Advisory Committee, Board of Trustees' Community Programs Committee, Internal Community Benefits Committee, and Community Benefits Office staff. A total of 38 individuals were engaged in this process including Gerry Thomas, Director, Community Initiatives Bureau, and Monica Valdez Lupi, Executive Director both from the Boston Public Health Commission. Part V, Line 7a DFCI's Community Health Needs Assessment Report is available on the DFCI Website at http://www.dana-farber.org/About-Us/Community-Outreach/Community-Health-Ne eds-Assessment-Reporting.aspx Part V, Line 10a DFCI's implementation strategy is available on the DFCI website. http://www.dana-farber.org/legacy/uploadedFiles/Library/about-us/community -outreach/chna-implementation-plan-2016.pdf Part V, Line 11 Dana-Farber Cancer Institute is addressing all the needs identified in the Community Health Needs Assessment and the accompanying Implementation Plans. A full description of our programs is available on our website both in the Community Health Needs Assessment Report and in the Community Health Implementation Plan. While our expertise as a comprehensive cancer center leads us to focus largely on reducing cancer incidence and mortality among medically underserved populations through our clinical community screening and outreach programs that include mobile mammography and breast health education, skin cancer education and screening, HPV education and vaccination, tobacco cessation and increasing awareness about survivorship in communities of color, we recognize that our priority neighborhoods are also dealing disproportionately with challenging situations related to social and economic factors such as limited employment opportunities, substance abuse and opioid addiction, low education levels, lack of affordable housing, and community violence, among others. We work on these broader issues by advocating and by partnering with local coalitions and community based organizations such as Boston Alliance for Community Health and member organizations. Part V, Line 22 Depending on a patient's financial situation, FAP-eligible patients were charged 0% to 30% of billed charges, which was not more than the AGB. In FY18, DFCI determined AGB on an annual basis using the "look-back method," described under Treasury Regulation Section 1.501(r)-5(b)(1). Specifically, DFCI's annual AGB percentage was equal to the sum of all gross charges during the prior fiscal year divided by Claims Paid in connection with those charges. For purposes of the AGB calculation, Claims Paid included claims for emergency and medically necessary care paid by both Medicare fee-for-service and all private health insurers as primary payers, together with any associated portions of these claims paid by Medicare beneficiaries or insured individuals in the form of co-payments, co-insurance or deductibles. Part V, Line 23 Following the end of FY18, DFCI determined through a detailed record review that one patient eligible under its Financial Assistance Program by virtue of their coverage under the Masachusetts Health Safety Net was charged and paid more than DFCI's AGB on 7/5/2018. The amount charged in excess of AGB totaled $240.04. See part VI, Supplemental Information regarding DFCI's correction of this failure. 1 DANA-FARBERNHOH ELLIOTT MED CENTER 40 BUTTRICK RD LONDONDERRY NH 03053 MED ONCOLOGY & INFUSION UNIT Part I, Line 3c In addition to determining eligibility for discounted care based on family income, DFCI offers assistance to patients who have excessive medical bills (exceeding 30-40% of family income). Part I, Line 6a The community benefit report was completed by DFCI and is annually provided to the Massachusetts Attorney General's office, where it is then made public on its website. Part I, Line 7 DFCI's State Cost Report was used to develop the Institute's cost to charge ratio that was applied to charity care charges to determine the cost of financial assistance cost (Line 7a). Line 7b reflects the specific loss incurred for the Institute's Medicaid activity. The Institution is a preeminent provider of heath training to health professionals who desire training in the skills necessary to treat cancer patients. The institution trains physicians, scientists, medical students and individuals looking to create a career in the field of cancer. The amounts reported as health training represent costs in excess of amounts reimbursed by third party payers such as training grant revenues and direct medical education payments from the Medicare Program. Department leaders submit expenditures to community benefits along with a description of the services provided to medically underserved populations. Line 7f expenditures are reviewed by leadership and in partnership with DFCI's office of Finance, the expenditures are approved. The amounts are captured in three buckets- CB expenditures(all programs); Leveraged Funds (those funds supported in full or part through grants/donation) and Community Sponsorships. Part II, Line 1 Physical Improvements and housing-DFCI provides a limited number of low cost rooms that serve as a home away from home for oncology patients and their families while they are receiving treatment. Part II, Line 8 To encourage underrepresented students of color to explore and pursue careers in health and science, Dana-Farber maintains educational partnerships with Boston area high schools and colleges. During Academic Year 2017-2018, 22 students participated in a college and career readiness training program. An additional 40 students were enrolled during the 2018 summer jobs program at Dana - Farber. Eligible students either attended or graduated from Boston public schools. During the 7-week summer program, students interned 30-hours per week and participated in college tours and career readiness workshops. Part III, Section A, Line 3 The amount of Bad Debt attributed to financial assistance patients is based on actual write-offs. The Bad Debt amount should be treated as a community benefit as it is similar to Unreimbursed Financial Assistance, as reported and allowed (Part I Line 7a), but for a different population. Part III, Line 2 and Line 4 The amount of Bad Debt of $11,272,243 comes directly from our General Ledger and is based on Bad Debt activity consistent with Generally Accepted Accounting Principles (GAAP). The Bad Debt Footnote is found on Audited Financial Statements - Pages 10 & 11 Part III, Line 8 The Medicare cost on line 6 comes from the Medicare cost report and is based on Medicare's cost finding principles and methodologies. We strongly believe that the entire amount of the shortfall of $20,438,724 should be treated as a community benefit as this represents the Institute's commitment to the elderly and disabled community by providing services that are not reimbursed. Part III, Line 9b Within DFCI's credit and collections policy there are provisions that describe collection practices to be followed for patients who are known to qualify for charity care or financial assistance in accordance with federal and Massachusetts law. Part V, Section A DFCI main campus is at 450 Brookline Ave., Boston, MA. DFCI's satellite locations (below) each operate under the same hospital license. Dana-Farber/Brigham and Women's Cancer Center at Milford Hospital 20 Prospect Street, Milford, MA 01757; Dana-Farber/Brigham and Women's Cancer Center at South Shore Hospital 101 Columbian Street, South Weymouth, MA 02190; and Dana-Farber at St. Elizabeth's Medical Center 736 Cambridge Street, Cushing Pavilion, 5th Floor, Brighton MA 02135 Part VI, Line 2 Needs Assessment Dana-Farber Cancer Institute continuously assesses the community needs through our participation in community coalitions, task forces, working groups and direct communication with the community residents that serve on our external advisory committee and in our patient and family advisory board. A full description of our community engagement process can be found on our website both in the Community Health Needs Assessment Report and in the Community Health Implementation Plan. Part VI, Line 3 DFCI is committed to offering financial assistance to eligible Patients who do not have the ability to pay for their medical services in whole or in part. In order to accomplish this charitable goal, DFCI widely publicizes its Patient Financial Assistance (PFA) Policy within its facilities, in direct communications with Patients and in the communities that it services, particularly in the communities with the greatest unmet health needs. The PFA Policy, a plain language PFA summary and the PFA application are posted on DFCI's website in English and Spanish. In addition, information about the PFA is provided to all patients at Registration and/or Admission, and is available upon request, without charge, through a DFCI Financial Counselor, Customer Service Representative, or by mail. Following care, all billing statements sent to a patient indicate how the patient can obtain information about the PFA Policy. In collaboration with DFCI's community partners, information about the FAP is shared with residents of DFCI's priority neighborhoods. Efforts to notify community members most likely to require assistance include distributing plain language summaries of this Policy to local community health centers and other non-profit organizations. Part VI, Line 4 DFCI serves the community of Eastern Massachusetts and New England, including the communities surrounding its primary location in Boston and its satellite locations in Milford, Massachusetts, Weymouth, Massachusetts, Brighton, Massachusetts and Londonderry, New Hampshire. DFCI's community includes adults and children with cancer or at risk of developing cancer, and their families. DFCI focuses its community outreach efforts on its priority Boston neighborhoods of Roxbury, Mission Hill, Dorchester, Mattapan and Jamaica Plain (which collectively comprise 39% of Boston's overall population). Two of Boston's most populated neighborhoods are DFCI's priority neighborhoods Dorchester with 122,598 residents, followed by Roxbury with 49,028. White residents now make up less than half of the city's racial and ethnic composition (46%). Black or African American residents were the second largest racial and ethnic group (23%), followed by Hispanics (18%) and Asians (9%). There is substantial variation in the racial and ethnic diversity by DFCI priority neighborhood, with nearly three-quarters of Mattapan residents and half of Roxbury residents identifying as Black or African American. Among DFCI priority neighborhoods, Roxbury and Jamaica Plain have the largest Hispanic populations with 29% and 24% respectively, while Mission Hill and Dorchester have the largest Asian populations among the priority neighborhoods with 14% and 10% respectively. The median incomes of DFCI's priority communities are generally much lower than Boston overall, with Roxbury at a median income of $25,254, Mission Hill at $35,020, and Mattapan at $42,206. Many of DFCI's priority neighborhoods, Roxbury and Mattapan, which are more likely to have a greater population at the lower end of the income spectrum. Residents in DFCI's priority neighborhoods appear to experience higher rates of poverty than Boston overall. Female headed households are especially vulnerable, with 45% of Roxbury female-headed households living below the poverty line. Part VI, Line 5 Dana-Farber's 2016 Community Health Needs Assessment and Implementation Plan provide a robust description of our comprehensive cancer control programs and services. The report also provides a summary of accomplishments from our last needs assessment and sets forth our commitment to addressing the new opportunities to reduce the cancer burden in medically underserved communities in Boston. The reports can be found at http://www.dana-farber.org/About-Us/Community-Outreach/Community-Health-Ne eds-Assessment-Reporting.aspx. In addition, DFCI furthers its exempt purpose by promoting the health of the community through devoting the vast majority of its surplus funds to Institutional Supported Research (119 million), by providing financial assistance to patients unable to afford care and by maintaining a community board. Part VI, Line 7 State Filing of Community Benefit Report Massachusetts PART VI, SUPPLEMENTAL INFORMATION 501(r) Reporting under IRS Revenue Procedure 2015-21 Throughout FY18, DFCI had a document describing how we calculate "amounts generally billed" (AGB) posted on its external website. This document referenced AGB of 33.0%, which was based on FY16 rather than FY17 data. Although an updated calculation had been done using FY17 data, this updated number was not posted on the external website due to an administrative oversight. Upon realizing the error, DFCI corrected the problem by updating this document, listing the AGB based on FY17 data, 32.1%. In addition, DFCI has developed an annual FAP checklist to ensure timely updates to the document describing how it calculates AGB. Because DFCI's FAP provides that FAP-eligible patients receive a discount of at least 70% and therefore pay no more than 30% of charges, the failure to post the correct AGB did not impact whether any FAP-eligible patients were charged more than AGB. Following the end of FY18, DFCI determined through a detailed record review that one patient eligible under its Financial Assistance Program by virtue of their coverage under the Massachusetts Health Safety Net was charged and paid more than DFCI's AGB on 7/5/2018. The amounts charged in excess of AGB totaled $240.04. Upon identifying this error, DFCI restored the affected individual to the position they would have been in had the failure not occurred by refunding the difference between the amount paid and the AGB for the relevant charges. In order to prevent future failures of this type, DFCI has amended its FAP to more clearly address the treatment of deductibles determined and required by the state Health Safety Net program. true AMERICAN CANCER SOCIETY 250 Williams St Atlanta GA 30303 131788491 501(C)(3) 10000 CANCER RES AND DEVLP BE THE MATCH FOUNDATION 500 N 5th ST Minneapolis MN 55401 411704734 501(C)(3) 6000 CANCER RES AND DEVLP THE BOSTON HOUSE INC 229 Kent St Brookline MA 02446 042627411 501(C)(3) 12500 PROVIDES HOUSING Broad Institute Inc 415 Main St Cambridge MA 02142 263428781 501(C)(3) 300000 CANCER RES AND DEVLP EDWARD M KENNEDY INSTITUTE Columbia Point 210 Morrissey BLVD Boston MA 02125 270963869 501(C)(3) 25000 COMMUNITY SUPPORT FENWAY HIGH SCHOOL 174 Ipswich St BOSTON MA 02215 046719813 501(C)(3) 20000 COMMUNITY SUPPORT Friends of Dana-Farber 450 Brookline Ave Boston MA 02215 371613621 501(C)(3) 50000 CANCER RES AND DEVLP Harvard University 60 Oxford St Cambridge MA 02138 042103580 501(C)(3) 1254340 CANCER RES AND DEVLP INQUILINOS BORICUAS EN ACCION 405 Shawmut Ave Boston MA 02118 237090081 501(C)(3) 10000 COMMUNITY SUPPORT INTERNATIONAL PHYSICIANS FOR THE PREVENTION OF NU 339 Pleasant St 3rd Fl Malden MA 02148 042702110 501(C)(3) 10000 CANCER RES AND DEVLP LEUKEMIA & LYMPHOMA SOCIETY INC 1311 MAMARONECK AVENUE WHITE PLANES NY 10605 135644916 501(C)(3) 40000 CANCER RES AND DEVLP PROSTATE HEALTH EDUCATION NETWORK INC 500 Victory Rd 4th FL Quincy MA 02453 331042404 501(C)(3) 30000 CANCER RES AND DEVLP SOCIEDAD LATINA INC 1530 Tremont St Boston MA 02120 042678255 501(C)(3) 49000 COMMUNITY SUPPORT THE BREAST CANCER RESEARCH FOUNDATION 60 EAST 56TH STREET 8TH FLOOR NEW YORK NY 10022 133727250 501(C)(3) 10000 CANCER RES AND DEVLP Brigham and Women's Hospital 75 Francis St Boston MA 02115 042312909 501(C)(3) 5373333 CANCER RES AND DEVLP WHITTIER STREET HEALTH CENTER 1125 TREMONT STREET ROXBURY MA 02120 042619517 501(C)(3) 154270 CANCER RES AND DEVLP 16 Patient Assistance 26 29568 Patient Assistance 2279 1414293 FMV ASST LIVING & TRAVEL Part IV ALL GRANTS AND DONATIONS WERE GIVEN TO 501(C)(3) ORGANIZATIONS TO FULFILL THEIR MISSIONS. X false true X X X X X false true false false false false false true false Glimcher Laurie Trustee, President and CEO 1112387 35137 0 0 231837 0 233810 0 12096 0 1590130 35137 0 0 Boskey Richard S ESQ Asst. SEC. & General Counsel 500568 0 85272 0 40772 0 38190 0 28448 0 693250 0 0 0 Puhy Dorothy COO & EVP 685042 0 172998 0 66802 0 38190 0 6302 0 969334 0 0 0 Reney Michael CFO and Asst. Treasurer 582757 0 91987 0 2292 0 38190 0 5476 0 720702 0 0 0 Bartel Sylvia R Ph MHP VP of Pharmacy Services 244427 0 28715 0 1729 0 35925 0 34485 0 345281 0 0 0 Bunnell Craig A MD MBA MPH Chief Medical Officer 580424 0 101812 0 43517 0 38190 0 6575 0 770518 0 0 0 Gettleman Wendy VP of Facilities Management 272053 0 26040 0 1027 0 27157 0 32074 0 358351 0 0 0 Johnson Bruce Chief Clinical Research Office 504648 0 91020 0 44483 0 36609 0 20777 0 697537 0 0 0 Megdal Maria SVP of Institute Operations 382875 0 79958 0 15688 0 38190 0 18150 0 534861 0 0 0 Memmott Drew SVP Research Administration 367440 0 62585 0 14369 0 37291 0 25898 0 507583 0 0 0 Paresky Susan SVP of Development 586643 0 99435 0 53541 0 38190 0 20979 0 798788 0 0 0 Rollins Barrett J MD PHD Chief Scientific Officer 546298 0 92318 0 46998 0 38190 0 18735 0 742539 0 0 0 Ebert Benjamin MD PHD Chair of Med Oncology 129741 0 75000 0 332 0 14640 0 6470 0 226183 0 0 0 Liebow Elizabeth SVP Business Dev Clinical Plan 298897 0 51000 0 5437 0 38190 0 25293 0 418817 0 0 0 Constantine Michael MD Milford Med Dir-Hematology 602533 0 47545 0 46849 0 24690 0 29620 0 751237 0 0 0 Nadler Lee MD SVP for Experimental Medicine 565755 0 96744 0 54008 0 38190 0 21914 0 776611 0 0 0 Soiffer Robert MD Chief of Hemotologic Malig. 525651 0 121823 0 49796 0 38190 0 25361 0 760821 0 0 0 Winer Eric MD SVP,CHF CLINICAL STRAT OFFICER 540193 0 106573 0 94489 0 43190 0 14261 0 798706 0 0 0 Hahn William MD PHD CHIEF RESEARCH STRATEGY OFFICE 484045 0 152560 0 36530 0 38190 0 4098 0 715423 0 0 0 Griffin James D MD Former Key Employee 573579 0 97323 0 51911 0 38190 0 23600 0 784603 0 0 0 Stone Richard M MD Former Key Employee 409523 0 28518 0 33184 0 38190 0 28358 0 537773 0 0 0 Benz Edward J JR MD Former Officer 944325 0 321957 0 99449 0 38190 0 16593 0 1420514 0 0 0 Bird Karen Former Officer 385234 0 0 4865 0 0 31404 0 421503 0 0 0 Sallan Stephen E MD Former Key Employee 437723 0 75700 0 30955 0 38190 0 26987 0 609555 0 0 0 Schedule J, Part I, Line 1a Membership Dues Dues DFCI paid membership dues on behalf of Susan Paresky the Sr. VP of Development, at the Harvard Club in Boston, MA. This positions responsibilities are those of fundraising. This membership provides use of space as well as important networking opportunities. The membership was utilized for business purposes, and therefoe was not included in taxable income. Schedule J, Part I, Line 4b The following individuals participate in DFCI's 457(f) plan; taxable amounts are included in reportable compensation in Schedule J, Part II, Column (B)(iii): Hahn, William MD 27,103 Benz, Edward J. Jr., MD 84,617 Boskey, Richard S., ESQ 29,891 Bunnell, Craig A. MD 39,252 Constantine, Michael, MD 42,388 Glimcher, Laurie MD 110,253 Griffin, James D., MD 38,884 Johnson, Bruce MD 29,924 Liebow, Elizabeth 4,313 Megdal, Maria 14,729 Memmott, Drew 12,959 Nadler, Lee, MD 38,452 Paresky, Susan 40,461 Puhy, Dorothy 52,325 Rollins, Barrett J., MD, PHD 35,149 Sallan, Stephen E., MD 22,747 Soiffer, Robert J., MD 33,496 Stone, Richard M MD 18,510 Winer, Eric, MD 32,897 Schedule J, Part I, Line 7 DURING THE YEAR, THE CEO, COO, CFO, GENERAL COUNSEL AND CERTAIN KEY EMPLOYEES AND HIGHEST COMPENSATED EMPLOYEES WERE ELIGIBLE TO RECEIVE AN INCENTIVE PAYMENT, A PORTION OF WHICH HAS A NON-FIXED PAYMENT PAYABLE AT THE DISCRETION OF THE CEO AND IN THE CASE OF THE CEO, THE BOARD OF TRUSTEES, IF THE ORGANIZATION MEETS CERTAIN FINANCIAL PERFORMANCE GOALS. THE MAXIMUM NON-FIXED PORTION OF THESE INCENTIVE PAYMENTS IS BETWEEN 8% (CEO - 40% MAX, OF THAT 32% TEAM, 8% INDIVIDUAL) AND 4% (SVP - 20% MAX, OF THAT 16% TEAM AND 4% INDIVIDUAL; VP - 10% MAX, OF THAT 6% TEAM AND 4% INDIVIDUAL) Other reportable compensation includes current year vesting amounts in Dana-Farber Institute's Supplemental nonqualified retirement plan. Compensation for Karen Bird, Former Chief Financial Officer, is primarily derived from her work as Executive Director of the Alliance of Dedicated Cancer Centers (ADCC). The ADCC fully reimburses Dana-Farber Cancer Institute, Inc for her compensation and benefits related to her work at ADCC. The remainder of her compensation is derived from her work as a Senior Policy Advisor for Dana-Farber Cancer Institute, Inc. A Massachusetts Development Finance Agency 042456011 57586cz24 2008-05-22 296490068 See Part VI false false false B Massachusetts Development Finance Agency 043431814 2012-07-02 57500000 See Part VI false false false C Massachusetts Development Finance Agency 043431814 2015-08-03 92500000 See Part VI false false false D Massachusetts Development Finance Agency 043431814 2016-06-23 281786480 See Part VI false false false A 150000000 0 302103386 8450586 4119476 0 2015100 116494 0 90335422 197066308 0 2011 true false true true B 0 0 57500000 0 0 0 0 0 0 0 57500000 0 2012 true false true true C 0 0 92500000 0 0 0 0 0 0 0 92500000 0 2015 true false true true D 0 0 282856392 0 1655104 0 2486701 0 0 282856392 0 0 false false true true A false false true true true true 0.00000 0.00000 0.00000 false false 0.00000 false true B false false true true true true 0.00000 0.00000 0.00000 false false 0.00000 false true C false false true true true true 0.00000 0.00000 0.00000 false false 0.00000 false true D false false false true true 0.00000 0.00000 0.00000 false false 0.00000 false true A false false false true true true MORG STANLEY CAP SRV 39.8 false false true TRINITY FUNDING COMP 2.8 true false true B false false false true true true MORG STANLEY CAP SRV 39.8 false false false 0 false true C false false false true true true MORG STANLEY CAP SRV 39.8 false false false 0 false true D false false false true false false 0 false 0 false true A true B true C true D true Part I (Bond Issues): A (a) Issuer name: Massachusetts Health and Educational Facilities Authority, succeeded by Massachusetts Development Finance Agency A (f) Description of purpose: The bond issue was used to refund Pool J-1 issued on June 30, 1993; Pool J-2 issued on June 8, 1995;Pool M-2 issued on May 30, 2002; Series H issued on May 4, 2004; Series I issued on February 8, 2007 to partially finance the construction of the Yawkey Center for Cancer Care. B (f) Description of purpose: The bond issue was used to refund part of Series L-2 bonds issued on 5/22/2008. C (f) Description of purpose: The bond issue was used to refund Series L-1 bonds issued on 5/22/2008. D (f) Description of purpose: The bond issue was / will be used to partially cover the acquisition and fit-out of research space and vivarium at the Longwood Center; to partially cover the replacement of HVAC system at the Smith Building; to cover the relocation to, reconstruction and equipping of the Institute's Cell Manipulation Core Facility; and to cover the costs of bond issuance and interest during the construction period as well as other capital projects. Part IV (Arbitrage): A 2(c) Did the following apply "No rebate due" - rebate calculation was performed in October 2018 B 2(c) Did the following apply "No rebate due" - rebate calculation was performed in October 2018 C 2(c) Did the following apply "No rebate due" - rebate calculation was performed in October 2018 D 2(c) Did the following apply "No rebate due" - rebate calculation was performed in October 2018 A 4(b) Name of provider: Morgan Stanley Capital Services, Inc. B 4(b) Name of provider: Morgan Stanley Capital Services, Inc. C 4(b) Name of provider: Morgan Stanley Capital Services, Inc. A 5(b) Name of provider: Trinity Funding Company, LLC Bruce Johnson Employee Housing Loan X 400000 8333 false true true Drew Memmott Employee housing loan X 75000 43125 false true true Karen Bird Employee tuition assistance X 49550 16470 false true true Stephen Sallan Employee Tuition Assistance X 262081 41713 false true true 109641 X 771000 Letter from Donor X 320 8298819 Fair Market Value X 32 368820 Letter from Donor X Miscellaneous 11 199450 Letter from Donor false true false Schedule M, Part I, Line 33 DFCI received donations of art, books, and other goods that it displays in its properties. These goods have values that are either nominal or are not readily determinable and are, therefore, not included as revenue. PART VI, QUESTION 2 Family Relationship: John O'connor And Laura Sen Business Relationship: Richard Lubin, Christopher Hadley And Jane Brock-Wilson PART VI, QUESTION 4 The Articles were amended to include addressing cancer care and education throughout the world. PART VI, QUESTION 11 PROCESS USED TO REVIEW THE FORM 990 THE DANA-FARBER CANCER INSTITUTE TAX DEPARTMENT PROVIDES ALL FINANCIAL ANALYSIS AND OTHER INFORMATION TO BE INCLUDED ON THE TAX RETURN TO ITS EXTERNAL TAX PREPARER, ERNST & YOUNG LLP, WHICH PREPARES THE DRAFT RETURN. THE DRAFT RETURN IS THEN REVIEWED AND APPROVED BY THE DFCI TAX MANAGER, AS WELL AS THE DFCI OFFICE OF GENERAL COUNSEL AND SENIOR MANAGEMENT, BEFORE IT IS APPROVED AND SUBMITTED FOR DFCI AUDIT COMMITTEE REVIEW. AFTER THE AUDIT COMMITTEE APPROVES THE TAX RETURN, AN ELECTRONIC MESSAGE IS SENT TO ALL BOARD MEMBERS WITH A SECURE LINK TO THE TAX RETURN. THE BOARD HAS THE OPPORTUNITY TO REVIEW THE RETURN AND BRING ANY ISSUES TO THE ATTENTION OF THE APPROPRIATE EXECUTIVE MANAGEMENT INDIVIDUALS. A FINAL VERSION OF THE FORM IS APPROVED BY THE CFO AND FILED ELECTRONICALLY BY ERNST & YOUNG LLP WITH THE IRS. PART VI, QUESTION 12C Monitoring & Enforcement Of Conflict Of Interest policy The office of general counsel and the tax department draft a conflict of interest disclosure questionnaire each year and requires that all trustees, officers, and key employees fill out a questionnaire in order to identify potential disclosures for dfci's returns. The office of general counsel compiles the list of disclosures and gathers financial data from the accounts payable and payroll department for all organizations, employees, independent contractors, and other miscellaneous transactions which were disclosed by all individuals. Once all of this information is compiled, the office of general counsel and the tax department goes through each transaction and disclosure to determine what needs to be disclosed on the tax return. The tax department and the office of general counsel also discusses if there are any other known transactions that have not been disclosed. If there are any questions regarding such situation, the office of general counsel will discuss the questions with the individual trustees, officers and key employees involved. In addition, the process described above, the governance committee of the board of directors annually reviews any new conflict of interest disclosures and they address any issues that may arise. The governance committee is also responsible to bring any major issues related to the conflict of interest policy to the executive committee and the entire board if deemed necessary. Per dfci's conflict of interest policy, in order to avoid a conflict of interest or an appearance of a conflict of interest: 1. A TRUSTEE SHOULD NOT PARTICIPATE IN A VOTE ON A TRANSACTION IN WHICH THE TRUSTEE OR FAMILY MEMBER HAS A FINANCIAL INTEREST AND SHOULD DISCLOSE ANY POTENTIAL CONFLICT BEFORE DFCI ACTS ON THE TRANSACTION. 2. A TRUSTEE, A MEMBER OF HIS OR HER FAMILY, OR AN ENTITY WITH WHICH ONE OR MORE OF THEM HAS A MATERIAL INTEREST, MAY NOT DO BUSINESS WITH DFCI UNLESS EXPRESSLY AUTHORIZED BY DFCI AFTER FULL DISCLOSURE. 3. A TRUSTEE SHOULD FULLY DISCLOSE HIS OR HER ASSOCIATION (INCLUDING EMPLOYMENT, CONSULTING, OR MEMBERSHIP ON A GOVERNING BOARD BY THE TRUSTEE OR A FAMILY MEMBER) WITH AN ENTITY THAT COMPETES WITH OR HAS INTERESTS CONFLICTING WITH THOSE OF DFCI AND SHOULD REFRAIN FROM PARTICIPATING IN ANY VOTE IF THE VOTE AFFECTS DFCI. ONCE A DISCLOSURE HAS BEEN MADE, DFCI'S OFFICE OF GENERAL COUNSEL REVIEWS SUCH CONFLICT WITH THE CHAIR OF THE BOARD WHO DETERMINES IF A CONFLICT EXISTS. WHEN A CONFLICT EXISTS, THE APPROPRIATE COMMITTEE OF THE BOARD OF TRUSTEES DETERMINES IF A MORE ADVANTAGEOUS ALTERNATIVE WITHOUT A CONFLICT OF INTEREST EXISTS AND WHETHER ENTERING INTO THE ARRANGEMENT IS IN THE BEST INTEREST OF DANA-FARBER. PART VI, QUESTION 15A PROCESS FOR DETERMINING COMPENSATION OF PRESIDENT PER DFCI'S EXECUTIVE COMPENSATION PHILOSOPHY, ANNUALLY THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES REVIEWS THE PRESIDENT'S (DFCI'S CHIEF EXECUTIVE OFFICER) PERFORMANCE AND MAKES A RECOMMENDATION REGARDING COMPENSATION TO THE EXECUTIVE COMMITTEE. THE EXECUTIVE COMMITTEE ACTS ON THE RECOMMENDATION. TO ENSURE COMPLIANCE WITH THE PHILOSOPHY, THE COMPENSATION COMMITTEE BI-ANNUALLY COMMISSIONS AN INDEPENDENT REVIEW BY A THIRD PARTY EXECUTIVE COMPENSATION CONSULTANT TO COMPARE SUCH COMPENSATION WITH THAT OF OTHER SIMILARLY SITUATED INDIVIDUALS IN THE HEALTHCARE FIELD IN AND OUTSIDE OF THE REGION. THE DECISION OF THE EXECUTIVE COMMITTEE IS REPORTED TO THE FULL BOARD. ANNUALLY, FOLLOWING THE FILING OF FORM 990, DFCI COMPARES THE INFORMATION IT REPORTS FOR ITS PRESIDENT TO THE COMPENSATION OF PRESIDENTS/CEO'S AT OTHER AREA HEALTHCARE ORGANIZATIONS AS WELL AS OTHER INSTITUTIONS THAT ARE CONSIDERED DESIGNATED COMPREHENSIVE CANCER CENTERS. THE BOARD COMPLETED THIS PROCESS AS OF MAY 2018. PART VI, QUESTION 15B PROCESS FOR DETERMINING COMPENSATION OF OFFICERS AND KEY EMPLOYEES PER DFCI'S EXECUTIVE COMPENSATION PHILOSOPHY, ANNUALLY THE DFCI PRESIDENT REVIEWS THE PERFORMANCE OF OFFICERS AND KEY EMPLOYEES AND MAKES A RECOMMENDATION AS TO THEIR COMPENSATION TO THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES. THE COMPENSATION COMMITTEE APPROVES COMPENSATION FOR THOSE INDIVIDUALS BASED ON THAT RECOMMENDATION. TO ENSURE COMPLIANCE WITH THE PHILOSOPHY, THE COMPENSATION COMMITTEE BI-ANNUALLY RECEIVES THE REPORT OF AN INDEPENDENT REVIEW BY A THIRD PARTY EXECUTIVE COMPENSATION CONSULTANT TO COMPARE SUCH COMPENSATION WITH THAT OF OTHER SIMILARLY SITUATED INDIVIDUALS IN THE HEALTHCARE FIELD IN AND OUTSIDE OF THE REGION. THE APPROVAL OF THE COMPENSATION COMMITTEE IS REPORTED TO THE EXECUTIVE COMMITTEE OF THE BOARD OF TRUSTEES AND TO THE FULL BOARD. ANNUALLY, FOLLOWING THE FILING OF FORM 990S DFCI COMPARES THE COMPENSATION OF THESE INDIVIDUALS WITH THOSE AT OTHER AREA HEALTHCARE ORGANIZATIONS AS WELL AS OTHER INSTITUTIONS THAT ARE CONSIDERED DESIGNATED CANCER CENTERS. THE BOARD COMPLETED THIS PROCESS AS OF MAY 2018. PART VI, QUESTION 19 AVAILABILITY OF GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS TO THE PUBLIC WE CURRENTLY PROVIDE THE GOVERNING DOCUMENTS UPON REQUEST. THE GOVERNING DOCUMENTS ARE ALSO AVAILABLE TO THE PUBLIC ON THE SECRETARY OF THE COMMONWEALTH'S WEBSITE. CONFLICT OF INTEREST POLICY - DANA-FARBER CANCER INSTITUTE'S BOARD OF TRUSTEES CONFLICT OF INTEREST POLICY IS AVAILABLE UPON REQUEST. FINANCIAL STATEMENTS - THE ORGANIZATION USES THE SERVICES OF DIGITAL ASSURANCE CERTIFICATION LLC (DAC) TO REPORT ANNUAL AUDITED FINANCIAL STATEMENTS AND OTHER RELEVANT ORGANIZATIONAL INFORMATION AS REQUIRED BY CERTAIN REGULATORY AND TAX LAWS. DAC IS A WEBSITE (WWW.DACBOND.COM) FREE TO THE PUBLIC THAT PUBLISHES TAX-EXEMPT BOND ISSUERS' FINANCIAL AND LEGAL DOCUMENTS SUCH AS THE AUDITED FINANCIAL STATEMENTS. FISCAL YEAR 2001 THROUGH THE LATEST ISSUE DATE OF THE AUDITED FINANCIAL STATEMENTS FOR DANA-FARBER CANCER INSTITUTE, INC. CAN BE FOUND ON THE DAC WEBSITE. PART VII, SECTION B THE AMOUNT PAID TO SKANSKA USA BUILDING, INC. INCLUDED COSTS FOR BUILDING SERVICES AND MATERIALS. HOWEVER, THE ORGANIZATION WAS UNABLE TO OBTAIN INFORMATION TO BREAKOUT THE EXACT AMOUNT FOR MATERIAL COSTS. PART XI LINE 9 OTHER CHANGES IN NET ASSETS CHANGE IN INTEREST IN ASSETS HELD BY AFFILIATE $132,463,656 CHANGE IN VALUE OF SWAP AGREEMENT $11,797,568 PENSION ADJUSTMENT $5,244,357 ------------- TOTAL OTHER CHANGES IN NET ASSETS $149,505,581 Dana-Farber Inc 450 Brookline Avenue BP418 Boston MA 02215 043102433 INVEST MGMT MA 501(c)(3) 12A, TYPE I DFCI true Dana-Farber Trust Inc 450 Brookline Avenue BP418 Boston MA 02215 300195757 DFCI RE HOLDI MA 501(c)(3) 12a, type 1 DFCI true Dana-FarberPartners Cancer Care Inc 450 Brookline Avenue BP418 Boston MA 02215 043320640 Oncol Sup Org MA 501(c)(3) 12C, type 1 DFCI false RMSA Trust 450 Brookline Avenue BP418 Boston MA 02215 562656539 RETRMT TRUST MA 501(c)(9) DFCI true Friends of Dana-Farber Cancer Institute 450 Brookline Ave BP418 Boston MA 02215 371613621 Fundraising MA 501(c)(3) 12A, Type I DFCI true Dana-FarberChildren's Hosp Cancer Care 450 Brookline Avenue BP418 Boston MA 02215 043554536 Pediatric Onc MA 501(c)(3) 12A, type I NA Dana-Farber Cancer Care Network Inc 450 Brookline Avenue BP418 Boston MA 02215 465138314 ONCOLOGY CARE MA 501(c)(3) 509(A)(2) DFCI true false true true false false false false false false false false true false false true false false true true Dana-FarberPartners Cancer Care Inc o 35137 cash Dana-FarberPartners Cancer Care Inc r 246651 cash Dana-FarberPartners Cancer Care Inc l 49721409 cash Dana-Farber Inc r 52055014 cash Dana-Farber Inc s 248877152 cash Friends of Dana-Farber Cancer Institute Inc o 285253 Actual Expense Friends of Dana-Farber Cancer Institute Inc b 50000 Cash Friends of Dana-Farber Cancer Institute Inc c 660162 cash Friends of Dana-Farber Cancer Institute Inc o 12731 Cost RMSA Trust r 203378 Cash Dana-Farber Cancer Care Network Inc m 36537136 Cost Dana-Farber Cancer Care Network Inc r 42970949 Cost